TW263498B - - Google Patents

Info

Publication number
TW263498B
TW263498B TW083110229A TW83110229A TW263498B TW 263498 B TW263498 B TW 263498B TW 083110229 A TW083110229 A TW 083110229A TW 83110229 A TW83110229 A TW 83110229A TW 263498 B TW263498 B TW 263498B
Authority
TW
Taiwan
Prior art keywords
stands
optionally substituted
ring
hydrogen atom
hydrocarbon residue
Prior art date
Application number
TW083110229A
Other languages
English (en)
Chinese (zh)
Original Assignee
Takeda Pharm Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharm Industry Co Ltd filed Critical Takeda Pharm Industry Co Ltd
Application granted granted Critical
Publication of TW263498B publication Critical patent/TW263498B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
TW083110229A 1993-11-10 1994-11-05 TW263498B (OSRAM)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP28117893 1993-11-10
JP33748893 1993-12-28
JP3363794 1994-03-03
JP13855194 1994-06-21

Publications (1)

Publication Number Publication Date
TW263498B true TW263498B (OSRAM) 1995-11-21

Family

ID=27459814

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083110229A TW263498B (OSRAM) 1993-11-10 1994-11-05

Country Status (16)

Country Link
US (1) US5585385A (OSRAM)
EP (1) EP0652218B1 (OSRAM)
KR (1) KR950014108A (OSRAM)
CN (1) CN1052004C (OSRAM)
AT (1) ATE203024T1 (OSRAM)
AU (1) AU678295B2 (OSRAM)
BR (1) BR9404403A (OSRAM)
CA (1) CA2135440A1 (OSRAM)
DE (1) DE69427675T2 (OSRAM)
FI (1) FI945281A7 (OSRAM)
HU (1) HUT68810A (OSRAM)
IL (1) IL111590A0 (OSRAM)
NO (1) NO301764B1 (OSRAM)
NZ (1) NZ264887A (OSRAM)
RU (1) RU2135471C1 (OSRAM)
TW (1) TW263498B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69628484T2 (de) * 1995-03-24 2004-05-19 Takeda Chemical Industries, Ltd. Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
US5770590A (en) * 1995-03-24 1998-06-23 Takeda Chemical Industries, Ltd. Cyclic compounds, their prudiction and use
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
US6087373A (en) * 1997-09-23 2000-07-11 Merck & Co., Inc. Thrombin inhibitors
AU740447B2 (en) * 1997-09-23 2001-11-01 Merck & Co., Inc. Thrombin inhibitors
US6323214B1 (en) 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
US6727258B2 (en) 1997-10-29 2004-04-27 King Pharmaceutical Research & Development, Inc. Allosteric adenosine receptor modulators
WO2000012503A1 (en) * 1998-08-26 2000-03-09 Tanabe Seiyaku Co., Ltd. Naphthyridine derivatives and process for the preparation thereof
AU6228499A (en) * 1998-10-22 2000-05-08 Akzo Nobel N.V. Tetrahydropyridopyridine derivatives and intermediates for producing the same
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
WO2000074682A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Thrombin inhibitors
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
AU2002354104A1 (en) 2001-12-10 2003-06-23 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
NZ533540A (en) * 2002-01-18 2006-04-28 Kyorin Seiyaku Kk Fused bicyclic pyrimidine derivatives that act as effective tachykinin receptor antagonists such as NK1 to treat tachykinin receptor-related pathological conditions
AU2003211931A1 (en) * 2002-02-13 2003-09-04 Takeda Chemical Industries, Ltd. Jnk inhibitor
JP4494020B2 (ja) 2002-03-15 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション Hivインテグラーゼ阻害剤として有用なn−(置換ベンジル)−8−ヒドロキシ−1,6−ナフチリジン−7−カルボキサミド
WO2003080626A1 (en) * 2002-03-26 2003-10-02 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivative as tachykinin receptor antagonist
JP2006515847A (ja) * 2002-12-13 2006-06-08 ニューロジェン・コーポレーション カプサイシン受容体調節剤としてのカルボン酸、ホスフェート又はホスホネート置換キナゾリン−4−イルアミン類縁体
RU2229475C1 (ru) * 2003-03-06 2004-05-27 ООО "Исследовательский институт химического разнообразия 6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
AU2004276237B2 (en) * 2003-09-23 2008-08-21 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
WO2005030727A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CA2552965A1 (en) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited Carboxamide derivative and use thereof
KR100781704B1 (ko) * 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR056048A1 (es) * 2005-09-01 2007-09-12 Tanabe Seiyaku Co Compuesto tiomorfolina y procedimiento para preparar el mismo
RU2359962C1 (ru) * 2007-12-13 2009-06-27 Общество с ограниченной ответственностью "Консорциум-ПИК" (ООО "Консорциум-ПИК") Нейротропное средство и способ его получения
RU2429230C1 (ru) * 2010-05-27 2011-09-20 Учреждение Российской академии наук Институт проблем химико-энергетических технологий Сибирского отделения РАН (ИПХЭТ СО РАН) Способ получения n-метил-4-бензилкарбамидопиридиния йодида
US20140187533A1 (en) * 2011-03-03 2014-07-03 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CN102358730A (zh) * 2011-08-24 2012-02-22 济南赛文医药技术有限公司 一种小分子mek蛋白激酶抑制剂
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US9663533B2 (en) 2012-11-14 2017-05-30 Glaxosmithkline Llc Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors
BR112015032710A2 (pt) 2013-06-28 2017-07-25 Abbvie Inc inibidores de bromodomínio
PT3265087T (pt) 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3693369A3 (en) 2016-04-15 2020-09-09 AbbVie Inc. Bromodomain inhibitors
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
CN111093671A (zh) 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
EP4153598A1 (en) 2020-05-20 2023-03-29 AMO Ireland Azacoumarin and azathiocoumarin derivatives for use in optically active devices
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
RS66978B1 (sr) 2020-07-02 2025-07-31 Incyte Corp Triciklična jedinjenja uree kao inhibitori jak2 v617f
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
TW205037B (OSRAM) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
DE69106499T2 (de) * 1990-02-10 1995-06-29 Takeda Chemical Industries, Ltd., Osaka Chromenderivate, deren herstellung und verwendung.
US5143919A (en) * 1990-08-17 1992-09-01 Takeda Chemical Industries, Ltd. Thienopyridine derivatives and their pharmaceutical use
ATE124408T1 (de) * 1990-10-16 1995-07-15 Takeda Chemical Industries Ltd Heterozyklische aminderivate, deren herstellung und deren verwendung.
TW241258B (OSRAM) * 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
DE4215588A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Biphenylmethyl-substituierte Pyridone
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
US5482967A (en) * 1992-09-04 1996-01-09 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
JPH06298757A (ja) * 1993-04-15 1994-10-25 Kissei Pharmaceut Co Ltd ピペリジノ−3,4−ジヒドロカルボスチリル誘導体

Also Published As

Publication number Publication date
CN1107476A (zh) 1995-08-30
CN1052004C (zh) 2000-05-03
BR9404403A (pt) 1995-07-18
NO944252D0 (no) 1994-11-08
NO944252L (no) 1995-05-11
AU7773894A (en) 1995-05-18
KR950014108A (ko) 1995-06-15
FI945281L (fi) 1995-05-11
AU678295B2 (en) 1997-05-22
DE69427675T2 (de) 2002-05-16
HU9403230D0 (en) 1995-01-30
CA2135440A1 (en) 1995-05-11
EP0652218A1 (en) 1995-05-10
ATE203024T1 (de) 2001-07-15
IL111590A0 (en) 1995-01-24
US5585385A (en) 1996-12-17
FI945281A7 (fi) 1995-05-11
DE69427675D1 (de) 2001-08-16
EP0652218B1 (en) 2001-07-11
RU94040174A (ru) 1996-10-10
FI945281A0 (fi) 1994-11-09
RU2135471C1 (ru) 1999-08-27
NZ264887A (en) 1996-12-20
NO301764B1 (no) 1997-12-08
HUT68810A (en) 1995-05-19

Similar Documents

Publication Publication Date Title
TW263498B (OSRAM)
AU2001230564A1 (en) Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2352495A (en) Condensed heterocyclic compounds, their production and use as gnrh antagonists
IL142649A0 (en) Azole derivatives
CA2206005A1 (en) Aniline derivatives possessing an inhibitory effect of nitric oxide synthase
AU4216993A (en) Novel arylglycinamide derivatives and preparative processes therefor
AU2454295A (en) Novel fused indan derivative and pharmaceutically acceptablesalt thereof
WO1992019210A3 (en) Serotinin reuptake inhibitors for s.p.e.c.t imaging
MXPA04002569A (es) H6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas espirociclicas que controlan citocinas inflamatorias.
EP0949242A4 (en) AROMATIC AMINE DERIVATIVES HAVING AN INHIBITORY ACTION WITH RESPECT TO OUR
CA2307581A1 (en) Heterocyclic compounds having nos inhibiting action
AU7708394A (en) Indoline compound and 5-ht3 receptor antagonist containing the same as active ingredient
AU4632996A (en) Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein
AU5980094A (en) Morpholine derivative
EP0680960A4 (en) IMIDAZOLE COMPOUND.
NZ312791A (en) Penicillaminamide derivatives
CA2131722A1 (en) N,N'-Disubstituted Amide Derivative
EP0579836A4 (OSRAM)
EP1103548A4 (en) TRIAZOLONE DERIVATIVES, THEIR USE AND INTERMEDIATE CONNECTION THEREFOR
EP0924204A4 (en) 2-PHENYLMORPHOLIN-5-ON DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
WO1999059996A8 (en) Antitumour 1,5-diazaanthraquinones
GB9318790D0 (en) Heterocyclic derivatives
AU7332996A (en) Therapeutics for thrombocytopenia
CA2247675A1 (en) Antifungal agents
CA2253635A1 (en) Use of aspirochlorine or derivatives thereof as immunosuppressive agents